Journal Article
. 2020 Oct; 12(563):.
doi: 10.1126/scitranslmed.aay3575.

Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy

David M Francis 1 Margaret P Manspeaker 1 Alex Schudel 2 Lauren F Sestito 3 Meghan J O'Melia 3 Haydn T Kissick 4 Brian P Pollack 4 Edmund K Waller 4 Susan N Thomas 5 
  • PMID: 32998971
  •     50 References
  •     33 citations


Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies (mAbs) can unleash antitumor functions of T cells but is associated with variable response rates and off-target toxicities. We hypothesized that antitumor efficacy of ICB is limited by the minimal accumulation of mAb within tissues where antitumor immunity is elicited and regulated, which include the tumor microenvironment (TME) and secondary lymphoid tissues. In contrast to systemic administration, intratumoral and intradermal routes of administration resulted in higher mAb accumulation within both the TME and its draining lymph nodes (LNs) or LNs alone, respectively. The use of either locoregional administration route resulted in pronounced T cell responses from the ICB therapy, which developed in the secondary lymphoid tissues and TME of treated mice. Targeted delivery of mAb to tumor-draining lymph nodes (TdLNs) alone was associated with enhanced antitumor immunity and improved therapeutic effects compared to conventional systemic ICB therapy, and these effects were sustained at reduced mAb doses and comparable to those achieved by intratumoral administration. These data suggest that locoregional routes of administration of ICB mAb can augment ICB therapy by improving immunomodulation within TdLNs.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Alena Gros, Maria R Parkhurst, +11 authors, Steven A Rosenberg.
Nat Med, 2016 Feb 24; 22(4). PMID: 26901407    Free PMC article.
Highly Cited.
Clonal replacement of tumor-specific T cells following PD-1 blockade.
Kathryn E Yost, Ansuman T Satpathy, +13 authors, Howard Y Chang.
Nat Med, 2019 Jul 31; 25(8). PMID: 31359002    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.
Edward Cha, Mark Klinger, +4 authors, Lawrence Fong.
Sci Transl Med, 2014 May 30; 6(238). PMID: 24871131    Free PMC article.
Highly Cited.
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon, Juliana Idoyaga, +19 authors, Miriam Merad.
Immunity, 2016 Apr 21; 44(4). PMID: 27096321    Free PMC article.
Highly Cited.
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.
Jan Willem Kleinovink, Koen A Marijt, +3 authors, Marieke F Fransen.
Oncoimmunology, 2017 May 17; 6(4). PMID: 28507803    Free PMC article.
Highly Cited.
Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.
Nathan Andrew Rohner, Susan Napier Thomas.
J Control Release, 2016 Jan 02; 223. PMID: 26721446    Free PMC article.
High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors.
Jolanda Brummelman, Emilia M C Mazza, +10 authors, Enrico Lugli.
J Exp Med, 2018 Aug 30; 215(10). PMID: 30154266    Free PMC article.
Highly Cited.
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.
Christiane Kümpers, Mladen Jokic, +6 authors, Patrick Terheyden.
Front Med (Lausanne), 2019 Apr 02; 6. PMID: 30931305    Free PMC article.
Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.
Luuk van Hooren, Linda C Sandin, +5 authors, Sara M Mangsbo.
Eur J Immunol, 2016 Nov 23; 47(2). PMID: 27873300
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation.
Hazem E Ghoneim, Yiping Fan, +8 authors, Ben Youngblood.
Cell, 2017 Jun 27; 170(1). PMID: 28648661    Free PMC article.
Highly Cited.
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Moshe Sade-Feldman, Keren Yizhak, +32 authors, Nir Hacohen.
Cell, 2018 Nov 06; 175(4). PMID: 30388456    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Brian C Miller, Debattama R Sen, +24 authors, W Nicholas Haining.
Nat Immunol, 2019 Feb 20; 20(3). PMID: 30778252    Free PMC article.
Highly Cited.
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice.
Iraklis C Kourtis, Sachiko Hirosue, +4 authors, Melody A Swartz.
PLoS One, 2013 Apr 30; 8(4). PMID: 23626707    Free PMC article.
Localized CD47 blockade enhances immunotherapy for murine melanoma.
Jessica R Ingram, Olga S Blomberg, +8 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2017 Sep 07; 114(38). PMID: 28874561    Free PMC article.
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Lidia Robert, Jennifer Tsoi, +11 authors, Antoni Ribas.
Clin Cancer Res, 2014 Mar 04; 20(9). PMID: 24583799    Free PMC article.
Highly Cited.
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
David A Knorr, Rony Dahan, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297432    Free PMC article.
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
Edward W Roberts, Miranda L Broz, +7 authors, Matthew F Krummel.
Cancer Cell, 2016 Jul 19; 30(2). PMID: 27424807    Free PMC article.
Highly Cited.
Material design for lymph node drug delivery.
Alex Schudel, David M Francis, Susan N Thomas.
Nat Rev Mater, 2020 Jun 12; 4(6). PMID: 32523780    Free PMC article.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Eradication of spontaneous malignancy by local immunotherapy.
Idit Sagiv-Barfi, Debra K Czerwinski, +4 authors, Ronald Levy.
Sci Transl Med, 2018 Feb 02; 10(426). PMID: 29386357    Free PMC article.
Highly Cited.
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison.
Cancer Discov, 2018 Aug 18; 8(9). PMID: 30115704
Highly Cited. Review.
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.
Sameena Khan, Deborah J Burt, +3 authors, Eyad Elkord.
Clin Immunol, 2010 Nov 09; 138(1). PMID: 21056008
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Pia Kvistborg, Daisy Philips, +13 authors, Ton N Schumacher.
Sci Transl Med, 2014 Sep 19; 6(254). PMID: 25232180
Highly Cited.
Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes.
Laura Kähäri, Ruth Fair-Mäkelä, +4 authors, Marko Salmi.
J Clin Invest, 2019 Jun 25; 129(8). PMID: 31232704    Free PMC article.
Intratumoral immunotherapy: using the tumor as the remedy.
A Marabelle, L Tselikas, T de Baere, R Houot.
Ann Oncol, 2017 Dec 19; 28(suppl_12). PMID: 29253115
Human Lymph Nodes Maintain TCF-1hi Memory T Cells with High Functional Potential and Clonal Diversity throughout Life.
Michelle Miron, Brahma V Kumar, +13 authors, Donna L Farber.
J Immunol, 2018 Aug 17; 201(7). PMID: 30111633    Free PMC article.
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
Andrew M Intlekofer, Craig B Thompson.
J Leukoc Biol, 2013 Apr 30; 94(1). PMID: 23625198    Free PMC article.
Highly Cited. Review.
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.
Caroline S Jansen, Nataliya Prokhnevska, +26 authors, Haydn Kissick.
Nature, 2019 Dec 13; 576(7787). PMID: 31827286    Free PMC article.
Highly Cited.
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Jedd D Wolchok, Bart Neyns, +14 authors, Celeste Lebbé.
Lancet Oncol, 2009 Dec 17; 11(2). PMID: 20004617
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats.
Leonid Kagan, Michael R Turner, Sathy V Balu-Iyer, Donald E Mager.
Pharm Res, 2011 Sep 03; 29(2). PMID: 21887597
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.
Alice O Kamphorst, Andreas Wieland, +17 authors, Rafi Ahmed.
Science, 2017 Mar 11; 355(6332). PMID: 28280249    Free PMC article.
Highly Cited.
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Se Jin Im, Masao Hashimoto, +13 authors, Rafi Ahmed.
Nature, 2016 Aug 09; 537(7620). PMID: 27501248    Free PMC article.
Highly Cited.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Kristian M Hargadon, Coleman E Johnson, Corey J Williams.
Int Immunopharmacol, 2018 Jul 11; 62. PMID: 29990692
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Margarida Viola, Joana Sequeira, +4 authors, António J Ribeiro.
J Control Release, 2018 Aug 06; 286. PMID: 30077735
Systemic Immunity Is Required for Effective Cancer Immunotherapy.
Matthew H Spitzer, Yaron Carmi, +10 authors, Edgar G Engleman.
Cell, 2017 Jan 24; 168(3). PMID: 28111070    Free PMC article.
Highly Cited.
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.
Greg M Thurber, Michael M Schmidt, K Dane Wittrup.
Adv Drug Deliv Rev, 2008 Jun 11; 60(12). PMID: 18541331    Free PMC article.
Highly Cited. Review.
Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
David M Francis, Susan N Thomas.
Adv Drug Deliv Rev, 2017 Apr 30; 114. PMID: 28455187    Free PMC article.
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
Kristen E Pauken, Morgan A Sammons, +16 authors, E John Wherry.
Science, 2016 Oct 30; 354(6316). PMID: 27789795    Free PMC article.
Highly Cited.
Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.
Marieke F Fransen, Tetje C van der Sluis, +2 authors, Cornelis J M Melief.
Clin Cancer Res, 2013 Jun 22; 19(19). PMID: 23788581
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Mauro Poggio, Tianyi Hu, +8 authors, Robert Blelloch.
Cell, 2019 Apr 06; 177(2). PMID: 30951669    Free PMC article.
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Marieke F Fransen, Mark Schoonderwoerd, +5 authors, Ferry Ossendorp.
JCI Insight, 2018 Dec 07; 3(23). PMID: 30518694    Free PMC article.
Highly Cited.
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Vikram R Juneja, Kathleen A McGuire, +5 authors, Arlene H Sharpe.
J Exp Med, 2017 Mar 18; 214(4). PMID: 28302645    Free PMC article.
Highly Cited.
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.
Melissa L Johnson, Fadi Braiteh, +7 authors, Siwen Hu-Lieskovan.
JAMA Oncol, 2019 May 31; 5(7). PMID: 31145415    Free PMC article.
Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.
Margaret P Manspeaker, Susan N Thomas.
Adv Drug Deliv Rev, 2020 Oct 16; 160. PMID: 33058931    Free PMC article.
Systematic Review.
Quality of CD8+ T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context.
M J O'Melia, N A Rohner, +3 authors, S N Thomas.
Sci Adv, 2020 Dec 15; 6(50). PMID: 33310857    Free PMC article.
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
Meghan J O'Melia, Margaret P Manspeaker, Susan N Thomas.
Cancer Immunol Immunother, 2021 Jan 19; 70(8). PMID: 33459842    Free PMC article.
In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy.
Jihoon Kim, David M Francis, Susan N Thomas.
Nanomaterials (Basel), 2021 Mar 07; 11(2). PMID: 33673289    Free PMC article.
Immunotherapy Goes Local: The Central Role of Lymph Nodes in Driving Tumor Infiltration and Efficacy.
Kim M van Pul, Marieke F Fransen, Rieneke van de Ven, Tanja D de Gruijl.
Front Immunol, 2021 Mar 19; 12. PMID: 33732264    Free PMC article.
Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
I-Tsu Chyuan, Ching-Liang Chu, Ping-Ning Hsu.
Cancers (Basel), 2021 Apr 04; 13(6). PMID: 33801815    Free PMC article.
Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy.
Florentine E F Timmer, Bart Geboers, +7 authors, Martijn R Meijerink.
Curr Oncol Rep, 2021 Apr 18; 23(6). PMID: 33864144    Free PMC article.
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.
Ignacio Melero, Eduardo Castanon, +2 authors, Aurelien Marabelle.
Nat Rev Clin Oncol, 2021 May 20; 18(9). PMID: 34006998    Free PMC article.
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
Koji Inamori, Yosuke Togashi, +13 authors, Hiroyoshi Nishikawa.
JCI Insight, 2021 Mar 24; 6(9). PMID: 33755600    Free PMC article.
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement.
Ai Lin Chin, Shan Jiang, +4 authors, Rong Tong.
Nat Commun, 2021 Aug 28; 12(1). PMID: 34446702    Free PMC article.
Pancreatic Cancer and Immunotherapy: A Clinical Overview.
Florentine E F Timmer, Bart Geboers, +12 authors, Tanja D de Gruijl.
Cancers (Basel), 2021 Aug 28; 13(16). PMID: 34439292    Free PMC article.
Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights.
Marieke F Fransen, Thorbald van Hall, Ferry Ossendorp.
Int J Mol Sci, 2021 Sep 11; 22(17). PMID: 34502307    Free PMC article.
Translational Applications of Hydrogels.
Santiago Correa, Abigail K Grosskopf, +4 authors, Eric A Appel.
Chem Rev, 2021 May 04; 121(18). PMID: 33938724    Free PMC article.
Strategies to sensitize cancer cells to immunotherapy.
Andrew George, Ilyas Sahin, +3 authors, Wafik S El-Deiry.
Hum Vaccin Immunother, 2021 May 22; 17(8). PMID: 34019474    Free PMC article.
Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade.
Yasuhiro Kanda, Taku Okazaki, Tomoya Katakai.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572844    Free PMC article.
Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance.
Chitavi D Maulloo, Shijie Cao, +8 authors, Jeffrey A Hubbell.
Front Immunol, 2021 Oct 12; 12. PMID: 34630389    Free PMC article.
Overcoming physical stromal barriers to cancer immunotherapy.
Seung Woo Chung, Yunxuan Xie, Jung Soo Suk.
Drug Deliv Transl Res, 2021 Aug 06; 11(6). PMID: 34351575    Free PMC article.
A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response.
Kelli A Connolly, Manik Kuchroo, +19 authors, Nikhil S Joshi.
Sci Immunol, 2021 Oct 02; 6(64). PMID: 34597124    Free PMC article.
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.
Haley du Bois, Taylor A Heim, Amanda W Lund.
Sci Immunol, 2021 Sep 14; 6(63). PMID: 34516744    Free PMC article.
Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting.
David M Francis, Margaret P Manspeaker, +4 authors, Susan N Thomas.
Biomaterials, 2021 Oct 23; 279. PMID: 34678650    Free PMC article.
Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties.
Natalija Van Braeckel-Budimir, Joseph Samuel Dolina, +14 authors, Shahram Salek-Ardakani.
J Immunother Cancer, 2021 Dec 15; 9(12). PMID: 34903555    Free PMC article.
Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth.
Anne Marijne Heeren, Jossie Rotman, +7 authors, Tanja D de Gruijl.
J Immunother Cancer, 2021 Oct 27; 9(10). PMID: 34697217    Free PMC article.
Maximizing response to intratumoral immunotherapy in mice by tuning local retention.
Noor Momin, Joseph R Palmeri, +8 authors, K Dane Wittrup.
Nat Commun, 2022 Jan 12; 13(1). PMID: 35013154    Free PMC article.
The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.
Huan Tong, He Wei, Alhaji Osman Smith, Juan Huang.
Front Immunol, 2022 Jan 25; 12. PMID: 35069586    Free PMC article.
Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes.
Noelle Leary, Sarina Walser, +8 authors, Lothar C Dieterich.
J Extracell Vesicles, 2022 Feb 22; 11(2). PMID: 35188342    Free PMC article.
Immunotherapeutic Approaches for the Treatment of HPV-Associated (Pre-)Cancer of the Cervix, Vulva and Penis.
Tynisha S Rafael, Jossie Rotman, +5 authors, Ekaterina S Jordanova.
J Clin Med, 2022 Feb 26; 11(4). PMID: 35207374    Free PMC article.
Synthetic Matrix Scaffolds Engineer the In Vivo Tumor Immune Microenvironment for Immunotherapy Screening.
Meghan J O'Melia, Adriana Mulero-Russe, +7 authors, Susan N Thomas.
Adv Mater, 2022 Jan 07; 34(10). PMID: 34989049    Free PMC article.
Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy.
Jihoon Kim, David M Francis, +4 authors, Susan N Thomas.
Nat Commun, 2022 Mar 20; 13(1). PMID: 35304456    Free PMC article.
Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes.
Louise Rethacker, Maxime Boy, +9 authors, Anne Caignard.
Oncoimmunology, 2022 Apr 05; 11(1). PMID: 35371620    Free PMC article.
The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development.
Zacharias Fasoulakis, Antonios Koutras, +14 authors, Emmanuel N Kontomanolis.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406423    Free PMC article.
Tumor-Draining Lymph Node Reconstruction Promotes B Cell Activation During E0771 Mouse Breast Cancer Growth.
Dante Alexander Patrick Louie, Darellynn Oo, +5 authors, Shan Liao.
Front Pharmacol, 2022 Apr 15; 13. PMID: 35418862    Free PMC article.
Standing Watch: Immune Activation and Failure in Melanoma Sentinel Lymph Nodes.
Amanda W Lund.
Clin Cancer Res, 2022 Mar 10; 28(10). PMID: 35262676    Free PMC article.
Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells.
Xiang Li, Jing Zhai, +5 authors, Lizong Shen.
Cancer Immunol Immunother, 2022 May 29;. PMID: 35633411